In the 2nd year of the Three-year Business Plan, BEACON 2030 Phase II,
Nihon Kohden will implement six key measures
and drive forward our transformation into a global MedTech company.
Hirokazu Ogino,
Representative Director,
President and Chief Executive Officer
First, we would like to express our heartfelt gratitude to our shareholders for your continued support.
We hereby report the results for the first half of FY2025 ending March 31, 2026.
In the first half of FY2025, domestic sales increased as the Company focused on its consumable and services business, while capital expenditure in hospitals was cautious. Overseas sales achieved double-digit growth on a comparable basis excluding the currency effect and the impact of the consolidation of Ad-Tech. Sales in North America, Europe, and Asia & Other increased favorably, while sales in Latin America decreased. Operating income increased due to increased sales and the consolidation of Ad-Tech. The increase in operating income was also because of the favorable gross profit margin due to higher selling prices and cost reductions of in-house products, as well as a decrease in inventory devaluation. Operating income for the first half fell short of the Company’s internal plan, as sales of locally purchased products were lower than expected in Japan and overseas sales also fell short of its expectations, mainly in Latin America and Asia & Other in the second quarter (three months). We expect to be able to recover in the second half of FY2025. The FY2025 full-year forecasts for overall sales, operating income, and ordinary income remain unchanged. The forecast for income attributable to owners of parent was revised, as we will record some expenses as extraordinary losses due to the implementation of Career Change Support Program and Next Career Support Program for Employees.
The interim dividend for the first half of FY2025 was 16 yen per share. The full-year dividend for FY2025 will be 32 yen per share.
The business environment surrounding the Company is entering an era of unprecedented paradigm shifts. Our Long-term Vision and Three-year Business Plan serve as guiding principles for building resilient organizational capabilities in response to these environmental changes. We firmly believe that embracing our challenges will drive our transformation into a global MedTech company with a sustainable competitive advantage.
FY2025 is a pivotal year for achieving the Three-year Business Plan. With strong determination, we will drive forward this transformation.
We deeply appreciate your continued support.
